GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coeptis Therapeutics Holdings Inc (NAS:COEP) » Definitions » Price-to-Tangible-Book

Coeptis Therapeutics Holdings (Coeptis Therapeutics Holdings) Price-to-Tangible-Book : 2.92 (As of May. 13, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Coeptis Therapeutics Holdings Price-to-Tangible-Book?

As of today (2024-05-13), Coeptis Therapeutics Holdings's share price is $0.3561. Coeptis Therapeutics Holdings's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $0.12. Hence, Coeptis Therapeutics Holdings's Price to Tangible Book Ratio of today is 2.92.

The historical rank and industry rank for Coeptis Therapeutics Holdings's Price-to-Tangible-Book or its related term are showing as below:

COEP' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.92   Med: 6.58   Max: 6.72
Current: 2.97

During the past 4 years, Coeptis Therapeutics Holdings's highest Price to Tangible Book Ratio was 6.72. The lowest was 2.92. And the median was 6.58.

COEP's Price-to-Tangible-Book is ranked worse than
55.98% of 1220 companies
in the Biotechnology industry
Industry Median: 2.71 vs COEP: 2.97

A closely related ratio is called PB Ratio. As of today, Coeptis Therapeutics Holdings's share price is $0.3561. Coeptis Therapeutics Holdings's Book Value per Sharefor the quarter that ended in Dec. 2023 was $0.12. Hence, Coeptis Therapeutics Holdings's P/B Ratio of today is 2.92.


Coeptis Therapeutics Holdings Price-to-Tangible-Book Historical Data

The historical data trend for Coeptis Therapeutics Holdings's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coeptis Therapeutics Holdings Price-to-Tangible-Book Chart

Coeptis Therapeutics Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
- - 6.72 6.43

Coeptis Therapeutics Holdings Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.72 - - 17.31 6.43

Competitive Comparison of Coeptis Therapeutics Holdings's Price-to-Tangible-Book

For the Biotechnology subindustry, Coeptis Therapeutics Holdings's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Coeptis Therapeutics Holdings's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coeptis Therapeutics Holdings's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Coeptis Therapeutics Holdings's Price-to-Tangible-Book falls into.



Coeptis Therapeutics Holdings Price-to-Tangible-Book Calculation

Coeptis Therapeutics Holdings's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Dec. 2023 )
=0.3561/0.122
=2.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Coeptis Therapeutics Holdings Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Coeptis Therapeutics Holdings's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Coeptis Therapeutics Holdings (Coeptis Therapeutics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
105 Bradford Road, Suite 420, Wexford, PA, USA, 15090
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio comprises multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
Executives
Tara Desilva director 105 BRADFORD RD., SUITE 420, WEXFORD PA 15090
David Mehalick director, 10 percent owner, officer: CEO and President 5000 TRESSDALE DRIVE, GIBSONIA PA 15044
Christopher P. Cochran director 105 BRADFORD RD., SUITE 420, WEXFORD PA 15090
Gene Salkind director 1165 WRACK ROAD, MEADOWBROOK PA 19046
Daniel Alexander Yerace director, officer: VP of Operations 402 SCHOMBURG COURT, CRANBERRY TOWNSHIP PA 16066
Chris Calise director, 10 percent owner, officer: Chief Financial Officer 801 S. POINTE DRIVE SUITE TH-1, MIAMI BEACH FL 33139
Philippe Deschamps director 105 BRADFORD RD, SUITE 420, WEXFORD PA 15090
Christine Elise Sheehy officer: CFO and Secretary 206 TAMARACK DRIVE, MARS PA 16046
Harraden Circle Investments, Llc 10 percent owner 299 PARK AVE, 21ST FLOOR, NEW YORK NY 10171
Harraden Circle Investors Gp, Lp 10 percent owner 299 PARK AVE., 21ST FLOOR, NEW YORK NY 10171
Harraden Circle Investors Gp, Llc 10 percent owner 299 PARK AVE., 21ST FLOOR, NEW YORK NY 10171
Fortmiller Frederick Vincent Jr. 10 percent owner 151 LULL ROAD, NEW BOSTON NH 03070
Harraden Circle Investors, Lp 10 percent owner 299 PARK AVENUE, 21ST FLOOR, NEW YORK NY 10171
Plc Barclays 10 percent owner 1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP
Paul J Glazer 10 percent owner 250 WEST 55TH ST, SUITE 30A, NEW YORK NY 10019

Coeptis Therapeutics Holdings (Coeptis Therapeutics Holdings) Headlines

From GuruFocus